Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

December 1, 2015

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

Previous Article
Medinol introduces NIRxcell CoCr Stent System to coronary marketplace
Medinol introduces NIRxcell CoCr Stent System to coronary marketplace

During the recent 2015 Transcatheter Cardiovascular Therapeutics Meeting held in San Francisco, CA, Medinol...

Next Article
St. Elizabeth Youngstown Hospital selects Sound Physicians to manage hospitalist services
St. Elizabeth Youngstown Hospital selects Sound Physicians to manage hospitalist services

Sound Physicians, a health care organization focused on improving quality and lowering cost throughout the ...